Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Methods for Screening a Therapeutic Agent of Heart Failure, Fibrosis and Inflammation and Compositions Comprising the Same
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Heart failure is associated with cardiac hypertropy, atheiosclerosis, myocardial infarction, valvular heart disease and hypertension. Many researches has focused on development of cardiotonics for treating heart failure....
Contact Yong U Kim
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
Novel drug target , Novel mechanism to treat heart failure, ?Little side effects

The core technology of Gwangju Institute of Science and Technology (GIST) is to provide a novel drug target and drug candidates to treat heart failure. The target molecule discovered by Ph. D Park is novel and effective in deveolpemnt of cardiotonic agents for treateing heart failure.


Background and unmet needs:  Heart failure is associated with cardiac hypertropy, atheiosclerosis, myocardial infarction, valvular heart disease and hypertension. Many researches has focused on development of cardiotonics for treating heart failure. However, conventional drugs developed so far have serious side effects such as arrhythmia and increased oxygen demand. In this regard, there remains to develop novel target molecules and drugs with more effective and little side effects in the art.


Discovery and Achievements:  The treatment efficacy of drug candidates developed by Ph.D Park is manifested by a molecular mechanism different from that of conventional cardiotonic agents. Specifically, the drug candidates increase calcium sensitivity in cardiac myocytes and in turn elevate myocardial contractility, exhibiting excellent treatment efficacy on heart failure. Interestingly, the drug candidates developed are accompanied with little side effects such as arrhythmia and increased oxygen demand that are usually associated with conventional cardiotonic agents, because they act on the novel biomolecular target governing a novel treatment mechanism.


Key Features and Advantages:


(a) Novel drug target


The target molecule discovered by Ph.D. Park is novel and effective in deveolpemnt of cardiotonic agents for treateing heart failure.


(b) Novel mechanism to treat heart failure


The treatment efficacy of drug candidates developed is manifested by a molecular mechanism different from that of conventional cardiotonic agents. Specifically, the drug candidates increase calcium sensitivity in cardiac myocytes and in turn elevate myocardial contractility, exhibiting excellent treatment efficacy on heart failure.


(c) Little side effects


The drug candidates developed are accompanied with little side effects such as arrhythmia and increased oxygen demand that are usually associated with conventional cardiotonic agents, because they act on the novel biomolecular target governing a novel treatment mechanism.

Type of Business Relationship Sought

FEATURED
Last Updated Jun 2016
Technology Type MECHANISM
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE